Yuya Nakamura, Masahiro Inagaki, Mayumi Tsuji, Toshihiko Gocho, Kazuaki Handa, Hitomi Hasegawa, Akihiko Yura, Tomoko Kawakami, Isao Ohsawa, Yoshikazu Goto, Hiromichi Gotoh, Yuji Kiuchi
BACKGROUND: Because of the potential anti-inflammatory effects, linagliptin, a therapeutic dipeptidyl peptidase-4 inhibitor, is used as an effective drug for diabetic patients for whom inflammation is a prognosis-related factor. We investigated the anti-inflammatory mechanism of linagliptin using seven markers. METHODS: We pretreated human umbilical vein endothelial cells (HUVECs), with linagliptin and lipopolysaccharide (LPS). The cytosolic fractions were evaluated for protein kinase A (PKA), protein kinase B (PKB), protein kinase C (PKC), ratio of reactive oxygen species (ROS) and Cu/Zn superoxide dismutase (SOD), activator protein 1 (AP-1), and adenosine 3',5'-cyclic monophosphate (cAMP)...
2016: Japanese Clinical Medicine